Overview
Adlai Nortye Ltd. is a biopharmaceutical company based in China, specifically involved in the research and development of innovative immunotherapies for cancer. The company operates primarily in the oncology sector, focusing its efforts on developing therapies that engage the body's own immune system to fight cancer. Key projects include a range of clinical-stage programs targeting various stages and types of cancer, with notable drugs in their pipeline being immune checkpoint inhibitors and bi-specific antibodies. Adlai Nortye is committed to advancing these programs through clinical trials with the aim of improving survival and quality of life for cancer patients worldwide. The company's strategic initiatives reflect a blend of scientific innovation and collaboration with global biotechnology entities to expedite the development and commercialization of its therapeutic products.
Quality, Value, Momentum Scores
This card shows the Quality, Value, and Momentum scores for the company
Income Statement: Revenue, Operating Income, Net Income
- The operating income for Adlai Nortye Ltd. - Depositary Receipt (Common Stock) as of December 31, 2024 is -52.93 MM.
- The net income for Adlai Nortye Ltd. - Depositary Receipt (Common Stock) as of December 31, 2024 is -51.87 MM.
| Period End (TTM) | Revenue (MM) | Operating Income (MM) | Net Income (MM) |
| 2024-12-31 | -52.93 | -51.87 | |
| 2024-09-30 | -61.30 | -55.15 | |
| 2024-06-30 | 5.00 | -64.67 | -54.06 |
| 2024-03-31 | 5.00 | -66.91 | -103.66 |
| 2023-12-31 | -72.55 | -109.23 | |
| 2023-09-30 | -71.57 | -115.94 | |
| 2023-06-30 | -70.58 | -122.65 | |
| 2023-03-31 | -71.24 | -62.74 | |
| 2022-12-31 | -67.27 | -58.79 | |
| 2021-12-31 | 45.73 | -8.65 | -56.68 |
| 2020-12-31 | -27.62 | -64.75 |
Income Statement: EPS
| Period End (TTM) | Earnings Per Share Basic | Earnings Per Share Diluted |
| 2024-12-31 | ||
| 2024-09-30 | ||
| 2024-06-30 | -2.32 | -2.32 |
| 2024-03-31 | -5.50 | -5.50 |
| 2023-12-31 | -7.26 | |
| 2023-09-30 | -9.92 | -9.92 |
| 2023-06-30 | -14.46 | -14.46 |
| 2023-03-31 | -7.40 | -7.40 |
| 2022-12-31 | -6.93 | |
| 2021-12-31 | -6.68 | |
| 2020-12-31 | -7.64 |
Cash Flow: Operations, Investing, Financing
- The cash from operating activities for Adlai Nortye Ltd. - Depositary Receipt (Common Stock) as of December 31, 2024 is -51.82 MM.
- The cash from investing activities for Adlai Nortye Ltd. - Depositary Receipt (Common Stock) as of December 31, 2024 is 28.07 MM.
- The cash from financing activities for Adlai Nortye Ltd. - Depositary Receipt (Common Stock) as of December 31, 2024 is -6.58 MM.
| Period End (TTM) | Cash From Operating Activities (MM) | Cash From Investing Activities (MM) | Cash From Financing Activities (MM) |
| 2024-12-31 | -51.82 | 28.07 | -6.58 |
| 2024-09-30 | -59.26 | 11.63 | 51.10 |
| 2024-06-30 | -66.70 | -4.81 | 108.79 |
| 2024-03-31 | -60.83 | -18.52 | 114.50 |
| 2023-12-31 | -56.65 | -10.95 | 116.24 |
| 2023-09-30 | -47.47 | 16.43 | 65.07 |
| 2023-06-30 | -38.28 | 43.81 | 13.91 |
| 2023-03-31 | -41.24 | 45.64 | 4.09 |
| 2022-12-31 | -43.22 | 28.38 | -6.78 |
| 2021-12-31 | -3.03 | -54.86 | 97.20 |
| 2020-12-31 | -32.85 | -2.03 | 53.07 |
Valuation Metrics : PE, PriceToBook, PriceToTBV
- P/Book
- The current closing price divided by the book value per share.
- P/TBV
- The current price divided by the tangible book value per share.
| Period End (TTM) | p/e | P/Book | P/TBV |
| 2024-12-31 | |||
| 2024-09-30 | |||
| 2024-06-30 | |||
| 2024-03-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 | |||
| 2021-12-31 | |||
| 2020-12-31 |
Valuation Metrics : EBitToEv, EBit3YrAvgToEv
| Period End (TTM) | EBIT/EV | EBIT (3y)/EV |
| 2024-12-31 | ||
| 2024-09-30 | ||
| 2024-06-30 | ||
| 2024-03-31 | ||
| 2023-12-31 | ||
| 2023-09-30 | ||
| 2023-06-30 | ||
| 2023-03-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | ||
| 2020-12-31 |
Management Effectiveness
- The roa for Adlai Nortye Ltd. - Depositary Receipt (Common Stock) as of December 31, 2024 is -0.42.
- The roe for Adlai Nortye Ltd. - Depositary Receipt (Common Stock) as of December 31, 2024 is -0.68.
- The roic for Adlai Nortye Ltd. - Depositary Receipt (Common Stock) as of December 31, 2024 is -0.58.
- The croic for Adlai Nortye Ltd. - Depositary Receipt (Common Stock) as of December 31, 2024 is 0.41.
- The ocroic for Adlai Nortye Ltd. - Depositary Receipt (Common Stock) as of December 31, 2024 is -0.72.
| Period End (TTM) | ROA | ROE | ROIC | CROIC | OCROIC |
| 2024-12-31 | -0.42 | -0.68 | -0.58 | 0.41 | -0.72 |
| 2024-09-30 | -0.42 | -0.68 | -0.58 | 0.41 | -0.72 |
| 2024-06-30 | -1.55 | -0.95 | 0.44 | -0.51 | |
| 2024-03-31 | -1.69 | ||||
| 2023-12-31 | -2.85 | 0.84 | -1.19 | ||
| 2023-09-30 | -3.07 | 0.46 | -0.96 | ||
| 2023-06-30 | -0.93 | -3.07 | 0.46 | -0.96 | |
| 2023-03-31 | -0.48 | -1.32 | 0.19 | -0.87 | |
| 2022-12-31 | |||||
| 2021-12-31 | -1.51 | -0.45 | 0.32 | -0.02 | |
| 2020-12-31 | -1.95 | 0.55 | -0.99 |
Gross Margins
- The gross margin for Adlai Nortye Ltd. - Depositary Receipt (Common Stock) as of December 31, 2024 is 1.00.
- The net margin for Adlai Nortye Ltd. - Depositary Receipt (Common Stock) as of December 31, 2024 is -10.81.
- The operating margin for Adlai Nortye Ltd. - Depositary Receipt (Common Stock) as of December 31, 2024 is -12.93.
- Gross Margin
- The Gross Margin is the ratio of revenue left after substracting the Cost of Goods Sold. It is calculated as 1.0 - (Revenue - COGS ) / Revenue.
- Net Margin
- The Net Margin (aka Profit Margin) is the ratio of revenue left after substracting the Net Income. It is calculated as Net Income / Revenue.
- Operating Margin
- The Operaing Margin is the ratio of revenue left after substracting the Operating Income. It is calculated as Operating Income / Revenue.
| Period End (TTM) | Gross Margin | Net Margin | Operating Margin |
| 2024-12-31 | 1.00 | -10.81 | -12.93 |
| 2024-09-30 | 1.00 | -10.81 | -12.93 |
| 2024-06-30 | 1.00 | -20.97 | -13.51 |
| 2024-03-31 | |||
| 2023-12-31 | |||
| 2023-09-30 | |||
| 2023-06-30 | |||
| 2023-03-31 | |||
| 2022-12-31 | |||
| 2021-12-31 | 1.00 | -1.24 | -0.19 |
| 2020-12-31 |
Identifiers and Descriptors
| Central Index Key (CIK) |
